ReviewCell communication and signaling : CCS2024
Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution.
Review in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Corrigendum to: Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.Neuro-oncology · 2026Article
- Mesenchymal transitions reduce lamin A expression and nuclear stiffness to enhance confined migration in glioblastoma.Scientific reports · 2026Article
- Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors.Journal of neuro-oncology · 2026Article
- Comprehensive exploration of the role of multimodal programmed cell death- associated lncRNAs in the prognosis and immunity of glioma.Frontiers in immunology · 2026Article
- Isobavachalcone induces concurrent apoptosis and pyroptosis in anaplastic thyroid cancer cells by modulating the caspase-mediated cleavage of PARP and GSDME.American journal of cancer research · 2026Article
- PLX3397 attenuated tumor growth and remodeled tumor microenvironment of recurrent glioblastoma.Scientific reports · 2025Article
- Machine learning-based programmed cell death-related index to predict prognosis and immunotherapy response in skin cutaneous melanoma.Oncology letters · 2025Article
- CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe.Cell death & disease · 2025Article
- Molecular targets of vortioxetine mediating glioblastoma suppression revealed by gene and protein network analyses and molecular docking simulations.The international journal of neuropsychopharmacology · 2025Article
- Essential oil extract p‑cresol effect on CaBiomedical reports · 2025Article
- SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma.Cell death & disease · 2025Article
- Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma.Frontiers in cell and developmental biology · 2025Article
- Programmed cell death-related prognostic genes mediate dysregulation of the immune microenvironment in triple-negative breast cancer.Frontiers in immunology · 2025Article
- Updating on the Dual Role of Salivary Gland Epithelial Cell (SGEC) in Sjögren's Disease.Journal of inflammation research · 2025Review
- Exploring tumor microenvironment interactions and apoptosis pathways in NSCLC through spatial transcriptomics and machine learning.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common malignant brain tumor and has a dismal prognosis even under the current first-line treatment, with a 5-year survival rate less than 7%. Therefore, it is important to understand the mechanism of treatment resistance and develop new anti-tumor strategies. Induction of programmed cell death (PCD) has become a promising anti-tumor strategy, but its effectiveness in treating GBM remains controversial. On the one hand, PCD triggers tumor cell death and then release mediators to draw in immune cells, creating a pro-inflammatory tumor microenvironment (TME). One the other hand, mounting evidence suggests that PCD and inflammatory TME will force tumor cells to evolve under survival stress, leading to tumor recurrence. The purpose of this review is to summarize the role of PCD and inflammatory TME in the tumor evolution of GBM and promising methods to overcome tumor evolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.